ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OPNT Opiant Pharmaceuticals Inc

20.65
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Opiant Pharmaceuticals Inc NASDAQ:OPNT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.65 18.89 22.41 0 01:00:00

Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022

03/05/2022 1:00pm

GlobeNewswire Inc.


Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart


From Apr 2022 to Apr 2024

Click Here for more Opiant Pharmaceuticals Charts.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.  

The Company’s management team is scheduled to host a conference call and webcast with slides at 4:30 p.m. ET on Tuesday, May 10, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13728852. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667. Following the live webcast, an archived version of the call will be available on the website.

Tuesday May 10 @ 4:30 pm ET

Domestic:1-877-407-0792
International:1-201-689-8263
Conference ID:13728852
Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667

About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.For more information visit: www.opiant.com.

For Media and Investor Inquiries:Ben Atkins, Opiant(310) 598-5410batkins@opiant.com

1 Year Opiant Pharmaceuticals Chart

1 Year Opiant Pharmaceuticals Chart

1 Month Opiant Pharmaceuticals Chart

1 Month Opiant Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock